Abivax is a clinical-stage biotechnology company pioneering novel therapies for chronic inflammatory diseases. Its lead drug candidate, obefazimod, targets immune regulation to treat conditions like ulcerative colitis and Crohn’s disease. Patients with moderate-to-severe inflammation who seek alternatives to conventional treatments may benefit from its unique mechanism and promising trial results.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends